Consistently, tumor biopsies of BCC showed a 10q deletion containing SUFU, which was associated with the partial loss of SUFU function but was not sufficient to drive resistance to vismodegib in the absence of other co-occurring alterations, such as focal GLI2 amplifications [80]. This evidence concerns the gene GLI2 and neoplasm.